化疗联合恩度治疗非小细胞肺癌临床观察  被引量:20

化疗联合恩度治疗非小细胞肺癌临床观察

在线阅读下载全文

作  者:朱小生[1] 胡晓文[1] 操乐杰[1] 高圣堂[1] 徐飞[1] 夏淮玲[1] 

机构地区:[1]安徽医科大学附属省立医院呼吸科,合肥230001

出  处:《临床肺科杂志》2009年第2期194-195,共2页Journal of Clinical Pulmonary Medicine

基  金:安徽省2008年科技计划项目资助(编号08020303088)

摘  要:目的探讨恩度联合化疗的疗效、毒副作用及生存率影响。方法采用标准肺癌化疗方案(GP/NP)联合恩度15mg/天,观察2个以上疗程治疗后疗效并随访。结果恩度联合化疗有效率(CR+PR)达46.2%,明显优于单纯化疗,而毒副作用轻微。结论恩度联合化疗能增加疗效,毒副作用可以耐受,值得临床推广。Objective To evaluate the efficacy , safety and survival rate of EndostarTM (YH-16) combined with chemotherapy for non-small cell lung cancer (NSCLC). Methods The patients were treated with more than 2 cycles of standard chemotherapy regimen (GP/NP) combined with YH-16 (15 mg/d). The efficacy was observed and the patients were follow-up visited. Results The response rate ( CR + PR) of the treatment group obviously surpassed the control group (48. 1% versus 14. 3 % , P 〈 0. 005 ), and the toxicity was little. Conclusion Significant efficacy and safety against NSCLC were observed in YH-16 in combination with chemotherapy compared with chemotherapy alone. It is worthy of extensive clinical application.

关 键 词:化疗 恩度 肺癌 

分 类 号:R734.2[医药卫生—肿瘤] R285.1[医药卫生—临床医学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象